Plinabulin – Triple Combos

Plinabulin
Triple Combos

Plinabulin + nivolumab + ipilimumab

In collaboration with Bristol Myers Squibb, we commenced an investigator-initiated Phase 1/2 trial of Plinabulin at Rutgers University in combination with Opdivo (nivolumab), a PD-1 antibody, and Yervoy (ipilimumab), a CTLA-4 antibody, as a treatment for SCLC. This study investigates whether the addition of Plinabulin results in a reduction of immune-related side effects of PD-1 and CTLA-4 antibodies and provides efficacy synergy.

Plinabulin + nivolumab + chemo

In collaboration with Merck, we commenced an investigator-initiated Phase 1/2 trial of Plinabulin at Johns Hopkins University in combination with Keytruda (pembrolizumab), a PD-1 antibody, and platinum-based chemotherapy agents as a first-line treatment for NSCLC. This study investigates whether the addition of Plinabulin results in a reduction of immune-related side effects of PD-1 antibodies and a reduction in severe neutropenia caused by platinum-based chemotherapy.

Clinical Trials

For details of these two trials, please visit the below website.

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer